EffRx Pharmaceuticals, a provider of innovative drug delivery technologies that improve efficacy and tolerability of existing compounds, has established a worldwide collaboration with Kadmon, a global biopharmaceutical company, under which EffRx will generate effervescent formulations of products to be developed by Kadmon in both adult and pediatric orphan indications. Financial terms were not disclosed.
“Our collaboration with Kadmon further validates our thesis that there is an acute need for alternative drug delivery methods. Our effervescent technology is an innovative delivery option that provides patients with convenience and reduces pill burden,” said Christer Rosen, EffRx chairman and CEO.
“Alternative drug delivery strategies can be an important part of treatment success,” said Samuel D. Waksal, Ph.D., Kadmon chairman and CEO. “We are excited to partner with EffRx to develop formulations of certain therapies aimed at adult and pediatric orphan indications, with the goal of designing treatments that are more tolerable and ensure better treatment compliance.”